OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) major shareholder Jennifer Pritzker sold 302,369 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the sale, the insider directly owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. The trade was a 4.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
OrthoPediatrics Price Performance
OrthoPediatrics stock opened at $21.56 on Friday. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. OrthoPediatrics Corp. has a 52-week low of $14.42 and a 52-week high of $26.74. The firm has a market cap of $562.93 million, a PE ratio of -12.83 and a beta of 0.99. The company’s 50 day moving average is $21.97 and its two-hundred day moving average is $19.02.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The business had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. On average, research analysts expect that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several research analysts recently commented on KIDS shares. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. BTIG Research increased their price target on OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Truist Financial set a $22.00 price objective on OrthoPediatrics in a research report on Wednesday, August 5th. Finally, Piper Sandler restated an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $26.44.
Get Our Latest Stock Analysis on KIDS
About OrthoPediatrics
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Featured Stories
- Five stocks we like better than OrthoPediatrics
- Feed to Feat: Can Meta Unlock the AI Agent Cash Machine?
- Chime Finds Its Stride With a $590M Deal That Could Reshape Its Banking Model
- IBM and Lockheed Martin Turn a Swiss Defense Deal Into a Quantum Computing Bet
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
